polvo para solución para perfusión
Sponsors
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla, Hospital Universitario La Paz, Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca, Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
Conditions
Bacteriemia producida por P. aeruginosa.Chronic Kidney DiseaseKidney TransplantKidney transplantationadvanced chronic renal insufficiency
Phase 4
Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.
Not yet recruitingCTIS2023-508441-41-00
Target: 306Updated: 2025-07-25
MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE
EFFICACY OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK
BASED ON SELECTIVE BIOMARKERS (HLA
EPLETH DISPARITY AND IFN-γ ELISPOT) TO OPTIMIZE IMMUNOSUPPRESSIVE
TREATMENT IN LIVING DONOR KIDNEY TRANSPLANT PATIENTS (BIOIMMUN)
Not yet recruitingCTIS2025-520884-42-00
Target: 164Updated: 2025-01-30
Use of tacrolimus and MTOR inhibitors with anticipatory therapy vs. tacrolimus and mycophenolic acid with universal prophylaxis in renal recipients at high risk of post-transplant cytomegalovirus. Phase IV clinical trial (TIMTOR STUDY).
Not yet recruitingCTIS2025-520854-12-00
Target: 30Updated: 2026-01-20
Phase IV, randomized, open-label study comparing the use of Grafalon® versus Thymoglobulin® in non-sensitized patients who have received a kidney transplant at high risk of delayed graft function
Not yet recruitingCTIS2026-526938-23-00
Target: 104Updated: 2026-10-19